Period of time： 2001年4期
Publisher： Cognizant Communication Corporation
Founded in： 1985
Total resources： 2
ISSN： 1460-2148
Subject： R9 Pharmacy
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Anti-Cancer Drug Design,volume 16,issue 4
Menu
By Kovacic P., Wakelin1 L.P.G. in (2001)
Anti-Cancer Drug Design,volume 16,issue 4 , Vol. 16, Iss. 4, 2001-08 , pp.
Access to resources
Recommend
Antineoplastic agents 460. Synthesis of combretastatin A-2 prodrugs
By Pettit G.R., Moser B.R., Boyd1 M.R., Schmidt J.M., Pettit R.K., Chapuis J-C. in (2001)
Anti-Cancer Drug Design,volume 16,issue 4 , Vol. 16, Iss. 4, 2001-08 , pp.The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents
By Kicic A., Chua A.C.G., Baker E. in (2001)
Anti-Cancer Drug Design,volume 16,issue 4 , Vol. 16, Iss. 4, 2001-08 , pp.By Wood L., Leese1 M.P., Leblond1 B., Woo1 L.W.L., Ganeshapillai1 D., Purohit2 A., Reed2 M.J., Potter1 B.V.L., Packham G. in (2001)
Anti-Cancer Drug Design,volume 16,issue 4 , Vol. 16, Iss. 4, 2001-08 , pp.By Vinh T.K., Yee S.W., Kirby1 A.J., Nicholls1 P.J., Simons C. in (2001)
Anti-Cancer Drug Design,volume 16,issue 4 , Vol. 16, Iss. 4, 2001-08 , pp.By Weigand M., Hartung1 G., Roboz2 J., Sieger S., Wolf M., Sinn3 H., Schrenk3 H-H., Wiessler M., Frei E. in (2001)
Anti-Cancer Drug Design,volume 16,issue 4 , Vol. 16, Iss. 4, 2001-08 , pp.By Dodds12 H.M., Hanrahan1 J., Rivory12 L.P. in (2001)
Anti-Cancer Drug Design,volume 16,issue 4 , Vol. 16, Iss. 4, 2001-08 , pp.Spin-labeled 1-alkyl-1-nitrosourea synergists of antitumor antibiotics
By Gadjeva V., Koldamova1 R. in (2001)
Anti-Cancer Drug Design,volume 16,issue 4 , Vol. 16, Iss. 4, 2001-08 , pp.Reversal of P-glycoprotein associated multidrug resistance by new isoprenoid derivatives
By Hayashi1 M., Koike2 K., Rho14 M-C., Kuwano3 M., Kishiye2 T., Komiyama1 K. in (2001)
Anti-Cancer Drug Design,volume 16,issue 4 , Vol. 16, Iss. 4, 2001-08 , pp.